Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
601 vs Ranibizumab in BRVO
NCT04667897Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 601 in macular edema, branch retinal vein occlusion (BRVO), hemiretinal vein occlusion (HRVO), sponsored by 3S Guojian Pharmaceutical. Started Jan 2021; status: completed.
02
Drugs
601
03
Conditions
macular edemabranch retinal vein occlusion (BRVO)hemiretinal vein occlusion (HRVO)
Beyond the preview
Go deeper on NCT04667897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667897.